Current treatment of Crimean-Congo hemorrhagic fever in children

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 8, 2010, Pages 911-918

  Mardani, Masoud ^a   Rahnavardi, Mohammad ^a   Sharifi Mood, Batool ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

children; Crimean Congo hemorrhagic fever; pediatric; ribavarin; tick bite; treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; AMINOCAPROIC ACID; ASCORBIC ACID; CALCIUM CHLORIDE; DESMOPRESSIN; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RIBAVIRIN; TRANEXAMIC ACID;

AGE DISTRIBUTION; ANEMIA; BLEEDING; BLOOD; CHILD; CLINICAL FEATURE; CRIMEAN CONGO HEMORRHAGIC FEVER; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EXPOSURE; HEPATITIS C; HUMAN; INFECTION CONTROL; LABORATORY DIAGNOSIS; LIVESTOCK; PROGNOSIS; REVIEW; SURVIVAL; THROMBOCYTOSIS; TICK BITE; TISSUE; UNSPECIFIED SIDE EFFECT; VIRUS HEMORRHAGIC FEVER; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; IMMUNOTHERAPY; INSECT BITES AND STINGS; RIBAVIRIN; SKIN; TICKS;

EID: 77955569154     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.67     Document Type: Review

References (57)

1. Mardani M, Keshtkar-Jahromi M. Crimean-Congo hemorrhagic fever. Arch. Iran Med. 10(2), 204-214 (2007).
2. Chinikar S, Ghiasi SM, Hewson R, Moradi M, Haeri A. Crimean-Congo hemorrhagic fever in Iran and neighboring countries. J. Clin. Virol. 47(2), 110-114 (2010).
3. Maltezou HC, Andonova L, Andraghetti R et al. Crimean-Congo hemorrhagic fever in Europe: current situation calls for preparedness. Euro. Surveill. 15(10), 19504 (2010).
4. Sheikh AS, Sheikh AA, Sheikh NS et al. Bi-annual surge of Crimean-Congo haemorrhagic fever (CCHF): a five-year experience. Int. J. Infect. Dis. 9(1), 37-42 (2005).
5. Nabeth P, Cheikh DO, Lo B et al. Crimean-Congo hemorrhagic fever, Mauritania. Emerg. Infect. Dis. 10(12), 2143-2149 (2004).
6. Tall A, Sall AA, Faye O et al. Two cases of Crimean-Congo haemorrhagic fever (CCHF) in two tourists in Senegal in 2004. Bull. Soc. Pathol. Exot. 102(3), 159-161 (2009).
7. Mardani M, Rahnavardi M, Rajaeinejad M et al. Crimean-Congo hemorrhagic fever among health care workers in Iran: a seroprevalence study in two endemic regions. Am. J. Trop. Med. Hyg. 76(3), 443-445 (2007).
8. Izadi S, Salehi M, Holakouie-Naieni K, Chinikar S. The risk of transmission of Crimean-Congo hemorrhagic fever virus from human cases to first-degree relatives. Jpn J. Infect. Dis. 61(6), 494-496 (2008).
9. Saijo M, Tang Q, Shimayi B et al. Possible horizontal transmission of Crimean- Congo hemorrhagic fever virus from a mother to her child. Jpn J. Infect. Dis. 57(2), 55-57 (2004).
10. Izadi S, Naieni KH, Madjdzadeh SR, Nadim A. Crimean-Congo hemorrhagic fever in Sistan and Baluchestan Province of Iran, a case-control study on epidemiological characteristics. Int. J. Infect. Dis. 8(5), 299-306 (2004).
11. Ozkurt Z, Kiki I, Erol S et al. Crimean- Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J. Infect. 52(3), 207-215 (2006).
12. Swanepoel R, Shepherd AJ, Leman PA, Shepherd SP, Miller GB. A common-source outbreak of Crimean-Congo haemorrhagic fever on a dairy farm. S. Afr. Med. J. 68(9), 635-637 (1985).
13. Hoogstraal H. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J. Med. Entomol. 15(4), 307-417 (1979).
14. van Eeden PJ, van Eeden SF, Joubert JR, King JB, van de Wal BW, Michell WL. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part II. Management of patients. S. Afr. Med. J. 68(10), 718-721 (1985).
15. Altaf A, Luby S, Ahmed AJ et al. Outbreak of Crimean-Congo haemorrhagic fever in Quetta, Pakistan: contact tracing and risk assessment. Trop. Med. Int. Health 3(11), 878-882 (1998).
16. Smego RA Jr, Sarwari AR, Siddiqui AR. Crimean-Congo hemorrhagic fever: prevention and control limitations in a resource-poor country. Clin. Infect. Dis. 38(12), 1731-1735 (2004).
17. Maltezou HC, Maltezos E, Papa A. Contact tracing and serosurvey among healthcare workers exposed to Crimean- Congo haemorrhagic fever in Greece. Scand. J. Infect. Dis. 41(11-12), 877-880 (2009).
18. Dilber E, Cakir M, Acar EA et al. Crimean-Congo haemorrhagic fever among children in north-eastern Turkey. Ann. Trop. Paediatr. 29(1), 23-28 (2009).
19. Sharifi-Mood B, Mardani M, Keshtkar- Jahromi M, Rahnavardi M, Hatami H, Metanat M. Clinical and epidemiologic features of Crimean-Congo hemorrhagic fever among children and adolescents from southeastern Iran. Pediatr. Infect. Dis. J. 27(6), 561-563 (2008).
20. Tezer H, Sayli TR, Metin A, Koker Y, Devrim I, Ergonul O. Lymphocyte subgroups in children with CCHF: a marker for prognosis. J. Infect. 59(4), 291-293 (2009).
21. Tanir G, Tuygun N, Balaban I, Doksoz O. A case of Crimean-Congo hemorrhagic fever with pleural effusion. Jpn J. Infect. Dis. 62(1), 70-72 (2009).
22. Ahmeti S, Raka L. Crimean-Congo haemorrhagic fever in Kosova: a fatal case report. Virol. J. 3, 85 (2006).
23. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res. 64(3), 145-160 (2004).
24. Swanepoel R, Shepherd AJ, Leman PA et al. Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in southern Africa. Am. J. Trop. Med. Hyg. 36(1), 120-132 (1987). (Pubitemid 17033988)
25. Sharifi-Mood B, Metanat M, Ghorbani- Vaghei A, Fayyaz-Jahani F, Akrami E. The outcome of patients with Crimean-Congo hemorrhagic fever in Zahedan, southeast of Iran: a comparative study. Arch. Iran. Med. 12(2), 151-153 (2009).
26. Ergönül O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean- Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin. Infect. Dis. 39(2), 284-287 (2004).
27. Schwarz TF, Nsanze H, Ameen AM. Clinical features of Crimean-Congo haemorrhagic fever in the United Arab Emirates. Infection 25(6), 364-367 (1997).
28. Vorou R, Pierroutsakos IN, Maltezou HC. Crimean-Congo hemorrhagic fever. Curr. Opin. Infect. Dis. 20(5), 495-500 (2007).
29. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev. Infect. Dis. 11(Suppl. 4), S794-S800 (1989).
30. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res. 78(1), 125-131 (2008).
31. Izadi S, Salehi M. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo hemorrhagic fever patients: a case-control study. Jpn J. Infect. Dis. 62(1), 11-15 (2009).
32. Tasdelen Fisgin N, Ergonul O, Doganci L, Tulek N. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur. J. Clin. Microbiol. Infect. Dis. 28(8), 929-933 (2009).
33. Ergonul O. Crimean-Congo haemorrhagic fever. Lancet Infect. Dis. 6(4), 203-214 (2006).
34. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit. Care 10(4), 222 (2006).
35. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 86(5), 1327-1330 (2001).
36. Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology Am. Soc. Hematol. Educ. Program 179-186 (2007).
37. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90(7), 2515-2521 (1997).
38. Levi M, Cromheecke ME, de Jonge E et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 354(9194), 1940-1947 (1999).
39. Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16(1), 37-48 (2006).
40. Watts DM, Ussery MA, Nash D, Peters CJ. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am. J. Trop. Med. Hyg. 41(5), 581-585 (1989).
41. Tignor GH, Hanham CA. Ribavirin efficacy in an in vivo model of Crimean- Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res. 22(4), 309-325 (1993).
42. Paragas J, Whitehouse CA, Endy TP, Bray M. A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus. Antiviral Res. 62(1), 21-25 (2004).
43. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet 346(8973), 472-475 (1995).
44. Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin. Infect. Dis. 36(12), 1613-1618 (2003).
45. Metanat M S-MB, Salehi M, Alavi-Naini R. Clinical outcome in Crimean-Congo hemorrhagic fever: a five-year experience in the treatment of patients in oral ribavirin. Int. J. Virol. 2, 21-24 (2006).
46. Vassilenko SM, Vassilev TL, Bozadjiev LG, Bineva IL, Kazarov GZ. Specific intravenous immunoglobulin for Crimean- Congo haemorrhagic fever. Lancet 335(8692), 791-792 (1990).
47. Andersson I, Bladh L, Mousavi-Jazi M et al. Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus. J. Virol. 78(8), 4323-4329 (2004).
48. Rahnavardi M, Rajaeinejad M, Pourmalek F, Mardani M, Holakouie-Naieni K, Dowlatshahi S. Knowledge and attitude toward Crimean-Congo haemorrhagic fever in occupationally at-risk Iranian healthcare workers. J. Hosp. Infect. 69(1), 77-85 (2008).
49. van de Wal BW, Joubert JR, van Eeden PJ, King JB. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part IV. Preventive and prophylactic measures. S. Afr. Med. J. 68(10), 729-732 (1985).
50. Tang Q, Saijo M, Zhang Y et al. A patient with Crimean-Congo hemorrhagic fever serologically diagnosed by recombinant nucleoprotein-based antibody detection systems. Clin. Diagn. Lab. Immunol. 10(3), 489-491 (2003).
51. Cevik MA, Elaldi N, Akinci E et al. A preliminary study to evaluate the effect of intravenous ribavirin treatment on survival rates in Crimean-Congo hemorrhagic fever. J. Infect. 57(4), 350-351 (2008).
52. Buckingham SC. Tick-borne infections in children: epidemiology, clinical manifestations, and optimal management strategies. Paediatr. Drugs 7(3), 163-176 (2005).
53. Tatar A, Ozkurt Z, Kiki I. Genotoxic effect of ribavirin in patients with Crimean- Congo hemorrhagic fever. Jpn J. Infect. Dis. 58(5), 313-315 (2005).
54. Long CE, Voter KZ, Barker WH, Hall CB. Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo. Pediatr. Infect. Dis. J. 16(11), 1023-1028 (1997).
55. Andersson I, Karlberg H, Mousavi-Jazi M, Martinez-Sobrido L, Weber F, Mirazimi A. Crimean-Congo hemorrhagic fever virus delays activation of the innate immune response. J. Med. Virol. 80(8), 1397-1404 (2008).
56. World Health Organization Regional Office for Europe. Epidemiology of Crimean-Congo haemorrhagic fever virus: Turkey, Russian Federation, Bulgaria, Greece, Albania, Kosovo. 11 August 2008 www.euro.who.int/surveillance/ outbreaks/20080806-1 (Accessed 27 April 2010)
57. World Health Organization. Crimean- Congo haemorrhagic fever. November 2001 www.who.int/mediacentre/factsheets/ fs208/en (Accessed 27 April 2010)